Standout Papers

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised... 2019 2026 2021 2023 256
  1. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial (2019)
    Bernard Zinman, Vaishali Bhosekar et al. The Lancet Diabetes & Endocrinology

Immediate Impact

1 from Science/Nature 67 standout
Sub-graph 1 of 21

Citing Papers

Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review
2025 Standout
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
2025 Standout
3 intermediate papers

Works of Ingrid Holst being referenced

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
2019 Standout

Author Peers

Author Last Decade Papers Cites
Ingrid Holst 318 186 19 87 5 334
Vaishali Bhosekar 270 167 16 81 9 357
Maki Goda 200 124 18 86 9 352
Lalita Prasad‐Reddy 251 137 11 76 9 360
Knut Robert Andersen 329 171 22 58 5 352
Surya Panicker Rajeev 221 105 17 53 13 272
Wenying Huang 219 165 9 58 9 351
Thalia Panagiotopoulou 245 97 24 101 3 339
Charlotte C. van Ruiten 214 90 20 59 9 263
Tea Monk Fries 284 148 15 89 7 345
Kristin C. Carlsson Petri 257 116 18 160 10 327

All Works

Loading papers...

Rankless by CCL
2026